The public scrutiny of pharmaceutical company Mylan NV (NASDAQ: MYL ) has played out on social media as well. And for once, everyone seems to be on the same side. Mylan has come under fire after significantly ...
RBC's Randall Stanicky and team argue that the risks to Mylan (MYL) from the EpiPen pricing controversy are mainly of the headline variety, but that they still matter...and are unlikely to end any time soon. Along with Teva Pharmaceutical Industries, Impax Laboratories (IPXL) could also be a beneficiary of Mylan's political headaches.
- PR Newswire•4 days ago
HAYWARD, Calif., Aug. 22, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (IPXL) announced today that Richard A. Bierly was appointed to the Impax Board of Directors on August 19 and will also serve on the Board's Audit Committee. Mr. Bierly, 61, was most recently the Chief Financial Officer of Medivation, Inc. "We are delighted to welcome Rick to the board as he brings more than 35 years of broad experience in finance and accounting across the pharmaceutical industry to our Board of Directors," said Robert L. Burr, Chairman of the Board of Impax Laboratories.
Impax Laboratories Inc. (IPXL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||22.25 x 200|
|Ask||25.00 x 500|
|Day's Range||23.50 - 24.16|
|52wk Range||20.97 - 46.10|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||50.49|
|Avg Vol (3m)||858,273|
|Dividend & Yield||N/A (N/A)|